Table 1.

Peptide vaccines in clinical trials

	Number of active or completed clinical trialsa	Conditions being treated with peptide vaccines
Phase III	7	Cancer immunotherapies, Multiple sclerosis, Type 1 diabetes
Phase II	203	Cancer immunotherapies, Myelodysplastic syndrome, HIV, HBV, HCV, Cytomegalovirus, Myasthenia gravis, Influenza, Malaria (falciparum)
Phase I and Early Phase 1	307	Cancer immunotherapies, HIV, HPV, HBV, HCV, Age‐related macular degeneration, Respiratory syncytial virus, Malaria (vivax), Malaria (falciparum), Hand foot and mouth disease, Influenza, Multiple sclerosis, Alzheimer's disease, Listeria, Cat allergy, Ragweed allergy, House dust mite allergy, Grass allergy

^aClinical studies were found using “peptide vaccine” as a search term on ClinicalTrials.gov, withdrawn studies were excluded.